Martin Pass

4.2k citations

31 papers · 873 · h-index 16

Impact in

Oncology top 10%
- Cancer-related Molecular Pathways
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer
- TGF-β signaling in diseases
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms

Papers in

Molecular Biology 24
- DNA Repair Mechanisms 9
- PI3K/AKT/mTOR signaling in cancer 9
- Protein Kinase Regulation and GTPase Signaling 5
- Cancer therapeutics and mechanisms 4
Oncology 8
- Cancer Treatment and Pharmacology 2
- PARP inhibition in cancer therapy 2

Co-authors: Kurt G. Pike (6 shared papers)Steve Powell (2 shared papers)Mark J. Anderton (1 shared paper)Howard R. Mellor (1 shared paper)Alex Bell (1 shared paper)C Sadler (1 shared paper)Ruth Roberts (1 shared paper)Annabelle Heier (1 shared paper)
Journals: Bioorganic & Medicinal Chemistry Letters (7 papers)Cancer Research (6 papers)Journal of Medicinal Chemistry (4 papers)Molecular Cancer Therapeutics (2 papers)ACS Medicinal Chemistry Letters (1 paper)
Partner nations: United Kingdom United States France

In The Last Decade

Martin Pass

31 papers receiving 852 citations

Peers

Countries citing papers authored by Martin Pass

Since Specialization

Citations

This map shows the geographic impact of Martin Pass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Pass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Pass more than expected).

Fields of papers citing papers by Martin Pass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Pass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Pass. The network helps show where Martin Pass may publish in the future.

Co-authors

The 25 scholars most cited alongside Martin Pass, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Martin Pass Line = papers co-authored together Martin Pass links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors Toxicologic Pathology ·Mark J. Anderton, Howard R. Mellor, Alex Bell, C Sadler, Martin Pass, Steve Powell, Samantha J. Steele, Ruth Roberts, Annabelle Heier	2011	211
2	Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014 Bioorganic & Medicinal Chemistry Letters ·Kurt G. Pike, Karine Malagu, Marc Hummersone, Keith Menear, Heather M. E. Duggan, Sylvie Gomez, Niall M.B. Martin, Linette Ruston, Sarah L. Pass, Martin Pass	2013	166
3	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules Molecular Cancer Therapeutics ·Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich	2015	103
4	Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT Journal of Medicinal Chemistry ·Jason G. Kettle, S Brown, Claire Crafter, Barry R. Davies, Phillippa Dudley, Gary Fairley, Paul Faulder, Shaun Fillery, Hannah E. Greenwood, Janet Hawkins, Michael J. James, Keith M. Johnson, Clare D. Lane, Martin Pass, Jennifer H. Pink, Helen Plant, Sabina Cosulich	2012	45
5	Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study Neuro-Oncology ·Aurelija Jučaitė, Per Stenkrona, Zsolt Cselényi, Serena De Vita, Núria Buil‐Bruna, Katarina Varnäs, Alicia Savage, Andrea Varrone, Peter Johnström, Magnus Schou, Chris Davison, Andy Sykes, Venkatesh Pilla Reddy, Matthias Hoch, Ana Vázquez‐Romero, Mohammad Mahdi Moein, Christer Halldin, Melinda S. Merchant, Martin Pass, Lars Farde	2020	42
6	Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline Bioorganic & Medicinal Chemistry Letters ·Richard Ducray, Clifford D. Jones, Frédéric Jung, Iain Simpson, Jon Curwen, Martin Pass	2011	36
7	Bromobenzofuran-Based Non-peptide Antagonists of Angiotensin II: GR138950, a Potent Antihypertensive Agent with High Oral Bioavailability Journal of Medicinal Chemistry ·Duncan B. Judd, Michael D. Dowle, David Middlemiss, D. I. C. SCOPES, Barry C. Ross, Torquil I. Jack, Martin Pass, Elvira Tranquillini, J.E. Hobson	1994	33
8	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Robert H. Bradbury, Craig S. Harris, Laurent Hennequin, Mark Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa Klinowska, Andrew G. Leach, Rémy Morgentin, Martin Pass, Donald Ogilvie, Annie Olivier, Nicolas Warin, Emma Williams	2005	31
9	Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2 Journal of Medicinal Chemistry ·Kurt G. Pike, Jeff Morris, Linette Ruston, Sarah L. Pass, Ryan Greenwood, Emma Williams, Julie Demeritt, Janet D. Culshaw, Kristy Gill, Martin Pass, M. Raymond V. Finlay, Catherine J. Good, Craig Roberts, Gordon S. Currie, Kevin Blades, Jonathan Eden, Stuart E. Pearson	2015	25
10	Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R) Journal of Medicinal Chemistry ·Sébastien L. Degorce, Scott Boyd, Jon Curwen, Richard Ducray, Christopher T. Halsall, Clifford D. Jones, Franck Lach, Eva M. Lenz, Martin Pass, Sarah L. Pass, Catherine B. Trigwell	2016	23
11	Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors Bioorganic & Medicinal Chemistry Letters ·Vibha Oza, Susan Ashwell, Patrick Brassil, J. Breed, Jaychandran Ezhuthachan, Chun Deng, Michael Grondine, Candice L. Horn, DongFang Liu, Paul D. Lyne, Nicholas J. Newcombe, Martin Pass, Jon Read, Mei Su, Dorin Toader, Dingwei Yu, Yan Yu, Sonya Zabludoff	2012	19
12	Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors ACS Medicinal Chemistry Letters ·Bernard Barlaam, Elaine Cadogan, Andrew D. Campbell, Nicola Colclough, Allan Dishington, Stephen T. Durant, Kristin Goldberg, Lorraine Hassall, Gareth Hughes, Philip A. MacFaul, Thomas M. McGuire, Martin Pass, Anil S. Patel, Stuart E. Pearson, Jens Petersen, Kurt G. Pike, Graeme R. Robb, Natalie Stratton, Guohong Xin, Baochang Zhai	2018	19
13	Abstract 3343: The pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase. Cancer Research ·Sylvie M. Guichard, Elaine Brown, Rajesh Odedra, Adina Hughes, Dan Heathcote, Jen Barnes, Alan W. Lau, Steve Powell, Clifford D. Jones, Willem Nissink, Kevin M. Foote, Philip J. Jewsbury, Martin Pass	2013	18
14	Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1) Molecular Cancer Therapeutics ·Wassim Abida, Yung Jue Bang, Louise Carter, Analía Azaro, Matthew Krebs, Seock‐Ah Im, Chen Ying-xue, Núria Buil‐Bruna, Yan Li, David Eaton, Christine Stephens, Graham Ross, Martin Pass, Jordi Rodón, Emma Dean	2018	17
15	Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer Cancer Research ·Sylvie M. Guichard, Zoë Howard, Dan Heathcote, Mark J. Roth, Gareth Hughes, Jon Curwen, James William Thomas Yates, Armelle Logié, Sarah V. Holt, Christine M. Chresta, Barry R. Davies, Karine Malagu, Marc Hummersone, Sarah L. Pass, Stephen Green, Martin Pass	2012	16
16	Formal synthesis of the antitumour antibiotic CC-1065 Journal of the Chemical Society Perkin Transactions 1 ·R. Bolton, Christopher J. Moody, Martin Pass, Charles W. Rees, Gabriel Tojo	1988	16
17	Synthetic [5,5] trans-fused indane lactones as inhibitors of thrombin Bioorganic & Medicinal Chemistry Letters ·Martin Pass, R. Bolton, Steven J. Coote, Harry Finch, Sean J. Hindley, Andrew Lowdon, Edward McDonald, Jessica McLaren, Martin Owen, Neil Pegg, Christopher J. Mooney, Chi-Man Tang, Simon Parry, Champa Patel	1999	9
18	Novel 1,5-benzodiazepindione gastrin/CCKB antagonists Bioorganic & Medicinal Chemistry Letters ·Nicholas Bailey, Philip C. Box, Robin A. E. Carr, Jason Cooke, B. Evans, Harry Finch, Julie E. Head, Martin Pass, Parita Shah, J. R. WHEATCROFT	1997	8
19	Abstract 4909: Adaptive oncology phase 1 study of first-in-class inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib Cancer Research ·Yingxue Chen, Martin Pass, Nuria Bui Bruna, Christine Stephens, Andrew J. Pierce, Wouter Hanekom, Hani Gabra, Helen Tomkinson, Nidal Al‐Huniti	2018	7
20	Synthesis of the left-hand unit of the antitumour agent CC-1065 Journal of the Chemical Society Chemical Communications ·Christopher J. Moody, Martin Pass, Charles W. Rees, Gabriel Tojo	1986	5

About Martin Pass

Martin Pass is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry and Genetics, having authored 31 papers that have together received 873 indexed citations. Recurring topics across this work include DNA Repair Mechanisms (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Cancer therapeutics and mechanisms (4 papers), Glioma Diagnosis and Treatment (3 papers), Cancer Treatment and Pharmacology (2 papers), Adenosine and Purinergic Signaling (2 papers) and PARP inhibition in cancer therapy (2 papers). The work is most often cited by research in Oncology (250 citations), Molecular Biology (551 citations), Organic Chemistry (212 citations), Genetics (62 citations) and Cancer Research (81 citations). Martin Pass has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Kurt G. Pike, Steve Powell, Mark J. Anderton, Howard R. Mellor, Alex Bell, C Sadler, Ruth Roberts, Annabelle Heier, Karine Malagu and Linette Ruston. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Research, Journal of Medicinal Chemistry, Molecular Cancer Therapeutics and ACS Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Martin Pass

Impact in

Papers in i

In The Last Decade

Martin Pass

Peers

Countries citing papers authored by Martin Pass

Fields of papers citing papers by Martin Pass

All Works

About Martin Pass

Explore authors with similar magnitude of impact

Papers in